Tacrolimus with MMF + Group 2: Tacrolimus with Everolimus.
Pre-clinicalCompleted 0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
End Stage Renal Failure With Renal Transplant
Conditions
End Stage Renal Failure With Renal Transplant
Trial Timeline
Feb 1, 2013 → May 1, 2020
NCT ID
NCT01653847About Tacrolimus with MMF + Group 2: Tacrolimus with Everolimus.
Tacrolimus with MMF + Group 2: Tacrolimus with Everolimus. is a pre-clinical stage product being developed by Novartis for End Stage Renal Failure With Renal Transplant. The current trial status is completed. This product is registered under clinical trial identifier NCT01653847. Target conditions include End Stage Renal Failure With Renal Transplant.
What happened to similar drugs?
20 of 20 similar drugs in End Stage Renal Failure With Renal Transplant were approved
Approved (20) Terminated (2) Active (0)
✅Henagliflozin 5 mg Group + Henagliflozin 10 mg Group + Conventional therapy groupJiangsu Hengrui MedicineApproved
Hype Score Breakdown
Clinical
3
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01653847 | Pre-clinical | Completed |
Competing Products
20 competing products in End Stage Renal Failure With Renal Transplant